171 related articles for article (PubMed ID: 24820058)
1. Enzalutamide: looking back at its preclinical discovery.
Ha YS; Kim IY
Expert Opin Drug Discov; 2014 Jul; 9(7):837-45. PubMed ID: 24820058
[TBL] [Abstract][Full Text] [Related]
2. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
Maeda H; Saito A
Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
[TBL] [Abstract][Full Text] [Related]
3. Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer.
Bennett LL; Ingason A
Ann Pharmacother; 2014 Apr; 48(4):530-7. PubMed ID: 24458946
[TBL] [Abstract][Full Text] [Related]
4. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
[TBL] [Abstract][Full Text] [Related]
6. Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor.
Quintela ML; Mateos LL; Estévez SV; Calvo OF; Herranz UA; Afonso FJ; Santomé L; Aparicio LA
Cancer Treat Rev; 2015 Mar; 41(3):247-53. PubMed ID: 25638257
[TBL] [Abstract][Full Text] [Related]
7. Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.
Modena A; Ciccarese C; Fantinel E; Bimbatti D; Tortora G; Massari F
Expert Rev Anticancer Ther; 2015; 15(9):1037-48. PubMed ID: 26134919
[TBL] [Abstract][Full Text] [Related]
8. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
[TBL] [Abstract][Full Text] [Related]
9. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
Schalken J; Fitzpatrick JM
BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
[TBL] [Abstract][Full Text] [Related]
10. The evolving role of enzalutamide on the treatment of prostate cancer.
Nadal R; Bellmunt J
Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/pharmacodynamic drug evaluation of enzalutamide for treating prostate cancer.
Hong JH
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):361-369. PubMed ID: 29431540
[TBL] [Abstract][Full Text] [Related]
12. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
Molecules; 2020 May; 25(10):. PubMed ID: 32456317
[TBL] [Abstract][Full Text] [Related]
13. Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer.
Cerasuolo M; Maccarinelli F; Coltrini D; Mahmoud AM; Marolda V; Ghedini GC; Rezzola S; Giacomini A; Triggiani L; Kostrzewa M; Verde R; Paris D; Melck D; Presta M; Ligresti A; Ronca R
Cancer Res; 2020 Apr; 80(7):1564-1577. PubMed ID: 32029552
[TBL] [Abstract][Full Text] [Related]
14. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
15. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
Pilling AB; Hwang C
Prostate; 2019 Aug; 79(11):1347-1359. PubMed ID: 31228231
[TBL] [Abstract][Full Text] [Related]
16. Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer.
Keating GM
Drugs Aging; 2015 Mar; 32(3):243-9. PubMed ID: 25711765
[TBL] [Abstract][Full Text] [Related]
17. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
Zhang T; Zhu J; George DJ; Armstrong AJ
Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X
Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003
[TBL] [Abstract][Full Text] [Related]
20. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.
Fizazi K; Albiges L; Loriot Y; Massard C
Expert Rev Anticancer Ther; 2015; 15(9):1007-17. PubMed ID: 26313416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
